GeneDx: A Moment Of Reckoning As Market Awaits Q3 Testing Growth
GeneDx Holdings Corp. is poised for strong Q3 results, driven by expanding exome and genome testing in pediatric and neonatal settings.Key metrics for WGS include test volume growth and reimbursement
admin
